Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study (English)
- New search for: Gadgeel, S
- New search for: Peters, S
- New search for: Mok, T
- New search for: Shaw, A T
- New search for: Kim, D W
- New search for: Ou, S I
- New search for: Pérol, M
- New search for: Wrona, A
- New search for: Novello, S
- New search for: Rosell, R
- New search for: Zeaiter, A
- New search for: Liu, T
- New search for: Nüesch, E
- New search for: Balas, B
- New search for: Camidge, D R
- New search for: Gadgeel, S
- New search for: Peters, S
- New search for: Mok, T
- New search for: Shaw, A T
- New search for: Kim, D W
- New search for: Ou, S I
- New search for: Pérol, M
- New search for: Wrona, A
- New search for: Novello, S
- New search for: Rosell, R
- New search for: Zeaiter, A
- New search for: Liu, T
- New search for: Nüesch, E
- New search for: Balas, B
- New search for: Camidge, D R
In:
Annals of oncology
;
29
, 11
;
2214-2222
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
-
Contributors:Gadgeel, S ( author ) / Peters, S ( author ) / Mok, T ( author ) / Shaw, A T ( author ) / Kim, D W ( author ) / Ou, S I ( author ) / Pérol, M ( author ) / Wrona, A ( author ) / Novello, S ( author ) / Rosell, R ( author )
-
Published in:Annals of oncology ; 29, 11 ; 2214-2222
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2018-01-01
-
Size:9 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 29, Issue 11
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 2155
-
Developing prognostic models for advanced prostate cancer when the goal line keeps changingFu, S Y F / Chi, K N et al. | 2018
- 2157
-
How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studiesAscierto, P A / Marabelle, A et al. | 2018
- 2160
-
Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?Thai, A A / Solomon, B J et al. | 2018
- 2163
-
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)Marabelle, A. / Andtbacka, R. / Harrington, K. / Melero, I. / Leidner, R. / de Baere, T. / Robert, C. / Ascierto, P. A. / Baurain, J.-F. / Imperiale, M. et al. | 2018
- 2175
-
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesSmoragiewicz, M. / Bogaerts, J. / Calvo, E. / Marabelle, A. / Perrone, A. / Seymour, L. / Shalabi, A. / Siu, L. L. / Tabernero, J. / Giaccone, G. et al. | 2018
- 2182
-
Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeuticsNikanjam, M. / Cohen, P. R. / Kato, S. / Sicklick, J. K. / Kurzrock, R. et al. | 2018
- 2183
-
Human endogenous retroviruses and their implication for immunotherapeutics of cancerAttermann, A. S. / Bjerregaard, A.-M. / Saini, S. K. / Grønbæk, K. / Hadrup, S. R. et al. | 2018
- 2200
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancerArmstrong, A. J. / Lin, P. / Higano, C. S. / Sternberg, C. N. / Sonpavde, G. / Tombal, B. / Templeton, A. J. / Fizazi, K. / Phung, D. / Wong, E. K. et al. | 2018
- 2208
-
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancerLong, G. V. / Tykodi, S. S. / Schneider, J. G. / Garbe, C. / Gravis, G. / Rashford, M. / Agrawal, S. / Grigoryeva, E. / Bello, A. / Roy, A. et al. | 2018
- 2214
-
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyGadgeel, S / Peters, S / Mok, T / Shaw, A T / Kim, D W / Ou, S I / Pérol, M / Wrona, A / Novello, S / Rosell, R et al. | 2018
- 2223
-
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancersGłodzik, D / Purdie, C / Rye, I H / Simpson, P T / Staaf, J / Span, P N / Russnes, H G / Nik-Zainal, S et al. | 2018
- 2232
-
Immunological differences between primary and metastatic breast cancerSzekely, B. / Bossuyt, V. / Li, X. / Wali, V. B. / Patwardhan, G. A. / Frederick, C. / Silber, A. / Park, T. / Harigopal, M. / Pelekanou, V. et al. | 2018
- 2240
-
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trialMooi, J. K. / Wirapati, P. / Asher, R. / Lee, C. K. / Savas, P. / Price, T. J. / Townsend, A. / Hardingham, J. / Buchanan, D. / Williams, D. et al. | 2018
- 2247
-
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trialColevas, A D / Bahleda, R / Braiteh, F / Balmanoukian, A / Brana, I / Chau, N G / Sarkar, I / Molinero, L / Grossman, W / Kabbinavar, F et al. | 2018
- 2254
-
Oncogenes expand during evolution to withstand somatic amplificationWang, X / Li, X / Zhang, L / Wong, S H / Wang, M H T / Tse, G / Dai, R Z W / Nakatsu, G / Coker, O O / Chen, Z et al. | 2018
- 2261
-
Neoadjuvant rectal score: run with the hare and hunt with the houndsSclafani, F. / Kalaitzaki, E. / Cunningham, D. / Tait, D. / Brown, G. / Chau. I. et al. | 2018
- 2262
-
Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancerTaniguchi, Y / Takeda, M / Tamiya, A / Kasai, T / Atagi, S et al. | 2018
- 2263
-
A centralised multidisciplinary clinic approach for germ cell tumoursCrawford, S. M. et al. | 2018
- 2264
-
Reply to the letter to the editor 'A centralised multidisciplinary clinic approach for germ cell tumours' by CrawfordAlbany, C / Adra, N / Snavely, A / Cary, C / Masterson, T / Foster, R / Kesler, K / Ulbright, T / Cheng, L / Chovanec, M et al. | 2018
- 2265
-
Reply to the letter to the editor ‘Body mass index and 20-specific cancers—re-analyses of dose–response meta-analyses of observational studies’ by Markozannes et al.Choi, E. K. / Eisenhut, M. / van der Vliet, H. J. / Lee, K. H. / Shin, J. I. et al. | 2018
- 2266
-
ESCAT: a step in the right directionSilver, A J / Warner, J L et al. | 2018
- 2268
-
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principleDe Mattos-Arruda L. / Weigelt, B. / Cortes, J. / Won, H. H. / Ng, C. K. Y. / Nuciforo, P. / Bidard, F.-C. / Aura, C. / Saura, C. / Peg, V. et al. | 2018
- 2269
-
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCKnox, J. J. / Barrios, C. H. / Kim, T. M. / Cosgriff, T. / Srimuninnimit, V. / Pittman, K. / Sabbatini, R. / Rha, S. Y. / Flaig, T. W. / Page, R. D. et al. | 2018
- 2270
-
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study resultsAparicio, T. / Bouché, O. / Taieb, J. / Maillard, E. / Kirscher, S. / Etienne, P.-L. / Faroux, R. / Akouz, F. K. / El Hajbi, F. / Locher, C. et al. | 2018
- 2271
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessCzuczman, M. S. / Leonard, J. P. / Jung, S. / Johnson, J. L. / Hsi, E. D. / Byrd, J. C. / Cheson, B. D. et al. | 2018